Search

Your search keyword '"Pelley, Robert"' showing total 8 results
Start Over Author "Pelley, Robert" Search Limiters Available in Library Collection
8 results on '"Pelley, Robert"'

1. Prospective Clinical Study of Precision Oncology in Solid Tumors

Author

Sohal, Davendra P. S., Rini, Brian I., Khorana, Alok A., Dreicer, Robert, Abraham, Jame, Procop, Gary W., Saunthararajah, Yogen, Pennell, Nathan A., Stevenson, James P., Pelley, Robert, Estfan, Bassam, Shepard, Dale, Funchain, Pauline, Elson, Paul, Adelstein, David J., and Bolwell, Brian J.

Published
2016
Full Text
View/download PDF

4. Prospective Clinical Study of Precision Oncology in Solid Tumors

Author

Sohal, Davendra P. S., primary, Rini, Brian I., additional, Khorana, Alok A., additional, Dreicer, Robert, additional, Abraham, Jame, additional, Procop, Gary W., additional, Saunthararajah, Yogen, additional, Pennell, Nathan A., additional, Stevenson, James P., additional, Pelley, Robert, additional, Estfan, Bassam, additional, Shepard, Dale, additional, Funchain, Pauline, additional, Elson, Paul, additional, Adelstein, David J., additional, and Bolwell, Brian J., additional

Published
2015
Full Text
View/download PDF

5. Abstract 2372: Capture and molecular characterization of CTC in metastatic breast, prostate, colorectal, and renal cancer

Author

Williams, Anthony, primary, Rawal, Siddarth, additional, Ao, Zheng, additional, Lu, Bo, additional, Torres-Munoz, Jorge, additional, Rini, Brian, additional, Pelley, Robert, additional, Budd, G Thomas, additional, Borden, Ernest, additional, Zheng, Siyang, additional, Datar, Ram, additional, Tai, Yu-Chong, additional, and Cote, Richard, additional

Published
2012
Full Text
View/download PDF

6. A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer

Author

Laheru, Dan, primary, Croghan, Gary, additional, Bukowski, Ronald, additional, Rudek, Michelle, additional, Messersmith, Wells, additional, Erlichman, Charles, additional, Pelley, Robert, additional, Jimeno, Antonio, additional, Donehower, Ross, additional, Boni, Joseph, additional, Abbas, Richat, additional, Martins, Patricia, additional, Zacharchuk, Charles, additional, and Hidalgo, Manuel, additional

Published
2008
Full Text
View/download PDF

7. The shared vision

Author

Pelley, Robert

Subjects
Business communication -- Methods, Business, general, Methods
Abstract

Back in the days of the Roman Empire, there were no faxes, telexes or even simple telephones. When the new ambassador to Galilee weighed anchor, one could only hope that [...]

Published
1993

8. Prospective Clinical Study of Precision Oncology in Solid Tumors.

Author

Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, Procop GW, Saunthararajah Y, Pennell NA, Stevenson JP, Pelley R, Estfan B, Shepard D, Funchain P, Elson P, Adelstein DJ, and Bolwell BJ

Subjects
Adult, Aged, Antineoplastic Agents pharmacology, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms genetics, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Feasibility Studies, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Middle Aged, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics, Prospective Studies, Sequence Analysis, DNA, DNA, Neoplasm analysis, Gene Expression Profiling, Medical Oncology trends, Molecular Targeted Therapy trends, Neoplasms drug therapy, Neoplasms genetics, Precision Medicine
Abstract

Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0-2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact. Colorectal (25%), breast (18%), lung (13%), and pancreatobiliary (13%) cancers were the most common diagnoses. Median time from consent to result was 25 days (range = 3-140). Of 223 evaluable samples, 49% (n = 109) of patients were recommended a specific therapy, but only 11% (n = 24) received such therapy: 12 on clinical trials, nine off-label, three on-label. Lack of clinical trial access (n = 49) and clinical deterioration (n = 29) were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy., (© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results